MAIA Biotechnology, Inc. (MAIA)

USD 1.94

(-11.82%)

Operating Expenses Summary of MAIA Biotechnology, Inc.

  • MAIA Biotechnology, Inc.'s latest annual operating expenses in 2023 was 20.18 Million USD , up 27.23% from previous year.
  • MAIA Biotechnology, Inc.'s latest quarterly operating expenses in 2024 Q2 was 3.83 Million USD , down -3.84% from previous quarter.
  • MAIA Biotechnology, Inc. reported a annual operating expenses of 15.86 Million USD in annual operating expenses 2022, up 104.86% from previous year.
  • MAIA Biotechnology, Inc. reported a annual operating expenses of 7.74 Million USD in annual operating expenses 2021, up 11.0% from previous year.
  • MAIA Biotechnology, Inc. reported a quarterly operating expenses of 3.96 Million USD for 2024 Q1, down -38.06% from previous quarter.
  • MAIA Biotechnology, Inc. reported a quarterly operating expenses of 4.13 Million USD for 2023 Q1, down -20.69% from previous quarter.

Annual Operating Expenses Chart of MAIA Biotechnology, Inc. (2023 - 2019)

Historical Annual Operating Expenses of MAIA Biotechnology, Inc. (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 20.18 Million USD 27.23%
2022 15.86 Million USD 104.86%
2021 7.74 Million USD 11.0%
2020 6.97 Million USD 0.78%
2019 6.92 Million USD 0.0%

Peer Operating Expenses Comparison of MAIA Biotechnology, Inc.

Name Operating Expenses Operating Expenses Difference
AIM ImmunoTech Inc. 32.07 Million USD 37.079%
Ampio Pharmaceuticals, Inc. 9.26 Million USD -117.764%
Armata Pharmaceuticals, Inc. 11.64 Million USD -73.254%
Actinium Pharmaceuticals, Inc. 52 Million USD 61.188%
Azitra, Inc. 8.3 Million USD -143.091%
Can-Fite BioPharma Ltd. 8.93 Million USD -125.804%
Chromocell Therapeutics Corporation 6.86 Million USD -194.106%
Calidi Biotherapeutics, Inc. 28.99 Million USD 30.386%
CEL-SCI Corporation 31.47 Million USD 35.88%
iBio, Inc. 16.85 Million USD -19.713%
Lineage Cell Therapeutics, Inc. 33 Million USD 38.854%
Matinas BioPharma Holdings, Inc. 24.86 Million USD 18.822%
Navidea Biopharmaceuticals, Inc. 13.93 Million USD -44.868%
NovaBay Pharmaceuticals, Inc. 12.89 Million USD -56.477%
NanoViricides, Inc. 8.51 Million USD -136.991%
Oragenics, Inc. 5.45 Million USD -270.186%
BiomX Inc. 26.81 Million USD 24.732%
BiomX Inc. 26.81 Million USD 24.732%
Protalix BioTherapeutics, Inc. 32.05 Million USD 37.032%
Palatin Technologies, Inc. 34.67 Million USD 41.788%
Scorpius Holdings, Inc. 39.81 Million USD 49.311%